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Exposure to ubiquitous persistent organic
pollutants (POPs) such as polychlorinated
biphenyls (PCBs), dichlorodiphenyldichloro-
ethylene (DDE), and hexachlorobenzene
(HCB) has attracted attention in breast can-
cer etiology. These compounds have high sol-
ubility in lipids and long half-lives in
organisms, and are present in measurable
amounts in human tissues, blood, and milk.
Although the mechanistic actions of these
chemicals in carcinogenesis remain unclear,
studies showed that some POPs have the
potential to promote cancer development in
various experimental models such as rodents
and human cell lines. In vitro assays using
MCF-7 human breast cancer cells showed
that POPs can promote cell proliferation
(Andersson et al. 1999; Du et al. 2000; Soto
et al. 1995). POPs have also been shown to
inhibit epidermal growth factor withdrawal-
induced apoptosis (Davis et al. 2001). 
Despite the experimental evidence, con-
troversy still exists regarding breast carcino-
genic properties of POPs in humans. An
epidemiologic study ﬁrst suggested that DDE
blood concentration may be an important eti-
ologic factor in breast cancer (Wolff et al.
1993). This finding led epidemiologists to
address further the issue of environmental
exposure to POPs and their potential implica-
tion in breast cancer. In subsequent years,
several environmental epidemiology studies
on the subject were published and their ﬁnd-
ings were greatly variable. Reviews and meta-
analyses concluded, on the lack of evidence to
support the hypothesis, that POP exposure
could be linked to an increase in female
breast cancer risk (Calle et al. 2002; Laden
et al. 2001; Lopez-Cervantes et al. 2004). On
the other hand, some studies showed a posi-
tive correlation between POP levels and
breast cancer incidence (Aronson et al. 2000;
Charlier et al. 2003; Demers et al. 2002;
Hoyer et al. 2000; Romieu et al. 2000).
The variability in conclusions among epi-
demiologic studies might arise from method-
ologic challenges. One conclusion relates to
the lack of tools for past exposure to pollu-
tants assessment (Brody and Rudel 2003). In
most cases, biologic assessment of exposure
has been limited to measurements of blood or
tissue levels in samples collected around the
date of diagnosis. It is uncertain that blood or
tissue concentrations sampled a few years
before diagnosis reflect the body burden
during potentially critical time windows such
as fetal, neonatal, and pubertal periods.
Epidemiologic conclusions on the link
between POP exposure and breast cancer
development are still based on the premise
that single sampling is indicative of past POP
exposures, highlighting the need for tools to
assess lifetime toxicokinetic proﬁles (LTPs). 
Physiologically based pharmacokinetic
(PBPK) modeling represents a possible
approach to estimating POP exposure during
specific time windows. PBPK models are
mathematic representations of xenobiotic
pharmacokinetics (i.e., processes of absorp-
tion, distribution, metabolism, and excretion)
based on the physiologic and biochemical
parameters of a given organism (e.g.,
humans) and the physicochemical properties
of the selected xenobiotic (Krishnan and
Andersen 2001). Such models allow the pre-
diction of blood or tissue concentrations at a
given time after a given dose of the xenobi-
otic. Various types of physiologic changes,
which can be mathematically described
within a PBPK model, may affect the kinetics
of a compound in an individual throughout
his or her life. Examples of relevant physio-
logic changes are body weight variations,
excretion of POPs through lactation (Neville
et al. 1991), and physiologic changes due to
aging (Haddad et al. 2006; Price K et al.
2003; Price PS et al. 2003) or pregnancy
(Gentry et al. 2002, 2003). PBPK modeling
can also accommodate a variety of exposure
scenarios such as changes in the lifestyle of
the subject and geographic/temporal moni-
toring data on environmental levels of POPs.
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BACKGROUND: Despite experimental evidence, most epidemiologic studies to date have not
supported an association between exposure to persistent organic pollutants (POP) and breast cancer
incidence in humans. This may be attributable to difﬁculties in estimating blood/tissue POP con-
centration at critical time periods of carcinogenesis.
OBJECTIVES: In this work we aimed to develop a tool to estimate lifetime POP blood/tissue exposure
and levels during any hypothesized time window of susceptibility in breast cancer development.
METHODS: We developed a physiologically based pharmacokinetic (PBPK) model that can account
for any given physiologic lifetime history. Using data on pregnancies, height, weight, and age, the
model estimates the values of physiologic parameters (e.g., organ volume, composition, and blood
ﬂow) throughout a woman’s entire life. We assessed the lifetime toxicokinetic proﬁle (LTP) for var-
ious exposure scenarios and physiologic factors (i.e., breast-feeding, growth, pregnancy, lactation,
and weight changes).
RESULTS: Simulations for three POPs [hexachlorobenzene, polychlorinated biphenyl (PCB)-153,
PCB-180] using different lifetime physiologic proﬁles showed that the same blood concentration at
55 years of age can be reached despite totally different LTP. Aside from exposure levels, lactation
periods and weight proﬁle history were shown to be the factors that had the greatest impact on
the LTP. 
CONCLUSIONS: This new lifetime PBPK model, which showed the limitations of using a single
sample value obtained around the time of diagnosis for lifetime exposure assessment, will enable
researchers conducting environmental epidemiology studies to reduce uncertainty linked to past
POP exposure estimation and to consider exposure during time windows that are hypothesized to
be mechanistically critical in carcinogenesis.
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simulate exposure throughout life while con-
sidering such physiologic changes would be
very useful to assess past exposure during crit-
ical time windows.
In the past, several PBPK modeling efforts
have described the toxicokinetics of different
POPs. Many of these models are based on the
assumption that these chemicals, which are
highly lipophilic, are distributed uniformly
between blood and tissues according to their
contents in lipids (for PCBs: Anderson et al.
1977; Emond et al. 2005; Lutz et al. 1977,
1984; Tuey and Matthews 1977, 1980a,
1980b; for dioxins: Carrier 1991, Maruyama
et al. 2003; van der Molen et al. 1996; for
HCB: Yesair et al. 1986). Other models have
added diffusion limitation to the fat compart-
ment [Belﬁore et al. 2007 (mirex); Lee et al.
2002, 2007 (PCB-153); Parham and Portier
1998 (PCBs); You et al. 1999 (p,p´-DDE)] or
diffusion limitation between erythrocytes and
plasma [Lu et al. 2006 (HCB)] to their model
structure to improve model predictions of
animal kinetic data. Although the addition of
diffusion limitation has definitely had an
impact on the initial uptake phase on a short
time scale, it is not likely to be an important
determinant for the toxicokinetics on a scale
spanning many years. Most agree that parti-
tioning for these compounds is driven by
lipid solubility, and this has been corrobo-
rated with human and rodent in vivo data
(Haddad et al. 2000).
Our overall goal in this work was to
develop an exposure assessment tool that could
be used in breast cancer epidemiologic studies
to estimate lifetime POP blood/tissue exposure
and levels during any hypothesized time win-
dow of susceptibility in breast cancer develop-
ment. The speciﬁc objectives were to build a
generic PBPK model framework to simulate
POP toxicokinetics for any given physiologic
profile and exposure data, and to evaluate
through model simulation the impact of expo-
sure scenarios and different physiologic factors
such as pregnancy, lactation, and body weight
on the lifetime internal exposure profile and
the blood POP concentration at 55 years of
age, a surrogate time representing the age of
diagnosis. For the purposes of this study, three
POPs with half-lives varying from 6 to 27.5
years were chosen to run the simulations:
HCB; 2,2´,3,4,4´,5,5´-heptachlorobiphenyl
(PCB-180); and 2,2´,4,4´,5,5´-hexachloro-
biphenyl (PCB-153).
Methods
The development of this new PBPK model
framework for lifetime POP exposure in
women can be separated into three distinct
phases: model representation, model parame-
terization, and simulations. Model validation
could not be achieved because of the evident
lack of data—namely, a lifetime follow-up
study measuring blood concentration at dif-
ferent moments and controlling all the input
parameters. The model was coded using
Advanced Continuous Simulation Language
(ACSLXtreme, Aegis Technologies Group,
Inc., Huntsville, AL, USA) and is available
on request.
Model representation. For this model, the
woman is best functionally described as a net-
work of nine tissue compartments perfused by
blood circulation (Figure 1). Compartments
are chosen for their known relevance to POP
kinetics or in light of objectives of this study.
The liver is set as the compartment where
both intake via ingestion and metabolism (i.e.,
ﬁrst-pass organ) take place. Because POPs are
highly hydrophobic compounds, adipose tis-
sue is deﬁned as a compartment where signiﬁ-
cant chemical storage can occur. Because
mammary tissue is the cancer site studied and
is also an excretory organ (i.e., via lactation), it
is also described as a separate compartment.
Along with mammary and adipose tissues,
uterine tissue, placenta, and fetus are repre-
sented as compartments because of their varia-
tions during pregnancy and postpartum
periods (i.e., mainly volume change). The
brain is added as a potentially interesting
organ for the study of cognitive and motor
effects of POPs. Finally, remaining tissues or
organs, except for teguments (i.e., bones, nails,
hair, cartilage), are grouped into slowly per-
fused tissues (mainly the skin, skeletal muscles,
and heart) and richly perfused tissues based on
their volume:blood ﬂow ratio. 
Absorption. Absorption of POPs can
occur through different routes, but primarily
occurs through food intake. For the purpose
of this study, total intake is limited to a direct
input into the liver compartment, and each
POP is assumed to be completely bioavailable
through the gastrointestinal tract, thus involv-
ing a hepatic ﬁrst pass. 
Distribution. The distribution of POPs is
managed by blood ﬂow to different compart-
ments and partitioning from blood to tissues.
This process is described by using mass balance
differential equations (MBDEs) that assume
homogenous distributions in tissues, as follows:
[1]
where At represents the amount of chemical
in the compartment, Qt is the blood ﬂow per-
fusing the compartment, Pt:b is the tissue:
blood coefficient for the compartment, and
Ca and Ct are concentrations in arterial blood
and the tissue, respectively. 
Metabolism. Metabolism is assumed to be
essentially limited to the liver compartment,
and the rate is described by the product of the
hepatic extraction ratio (Eh), the liver blood
ﬂow (Ql), and the arterial blood concentration
(Ca) entering the compartment, as follows:
RAM = Ql × Eh × Ca . [2]
The value of Eh can be calculated from
available data such as half-life values,
Michealis-Menten constants (Vmax and Km),
or intrinsic clearances. The MBDE in the
liver therefore becomes
[3]
where Al, Cl, and Pl:blood are the amount, con-
centration, and tissue:blood partition coeffi-
cient of the POPs in the liver, respectively.
Excretion. Because most POPs are poorly
metabolized, the main elimination route
occurs through excretion of unchanged chem-
icals. The model is adapted for two excretion
pathways: lactation and parturition. POP
excretion via lactation is represented as an
output from the mammary tissue compart-
ment through a partitioning process between
mammary tissue and milk, and milk with-
drawal by the suckling such as described by
Lee et al. (2007) for PCBs in rats. This parti-
tioning process is further addressed in the
model parameterization section. The POP
excretion via lactation is described as follows:
[4]
and
[5]
where Amam and Cmam are the POP amount
and concentration in mammary tissue.
Qmam is the blood flow to mammary tissue
compartment, Qmilk refers to the milk flow
RAE Qmilk
Cmam
P
P
mam b
milk b =× ×
:
: ,
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Figure 1. Conceptual representation of the PBPK
model.
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Lactationout of the breast (i.e., the volume drunk per
hour by infant in liters per hour), and Pmam:b
and Pmilk:b are the mammary:blood and
milk:blood partition coefﬁcients. 
The placental transfer to the fetus is
described using published equations in
Gentry et al. (2002). The elimination of
chemicals through parturition is described as
a punctual extraction of the baby body and
placenta burdens at the time of birth. 
Model parameterization. To simulate
internal exposure in women throughout their
entire life, compartments size, blood ﬂows, and
biochemical properties are described as vari-
ables that change as a function of age, body
weight, body height, and pregnancy periods
(see Supplemental Material online at http://
www.ehponline.org/members/2008/10917/
suppl.pdf). Mathematical equations describing
these variable parameters are arranged so that
information on body weight and body height
in relation to age, collected from question-
naires, can be easily used as inputs throughout
the entire simulation. Volume and blood ﬂow
parameters for liver, richly perfused, slowly
perfused, and adipose tissue compartments are
taken from Haddad et al. (2006). The equa-
tions describing early stages of development are
used to calculate organs growth for the 0–1
year interval, because no data are available for
that period. Because of the lack of data, uterine
tissue and mammary tissue are set as a function
of body weight and age (Gentry et al. 2002).
Mammary tissue volume is assumed to start
from 0 L at 10 years of age and increase lin-
early to its ﬁnal volume at 14 years of age. 
Physiologic changes during pregnancy are
considered for the uterine tissue, mammary tis-
sue, adipose tissue, placenta, and fetus com-
partments based on time elapsed since the
beginning of pregnancy, as described by
Gentry et al. (2002). Postpartum changes are
set as a 6-month linear return to normal in the
volume of organs influenced by pregnancy
(Gentry et al. 2003). Blood ﬂow to these com-
partments varies proportionally to their volume
throughout pregnancy and postpartum
changes. Lactation parameters are also allowed
to change over the lactation period. Equations
describing changes in daily excreted milk vol-
ume and milk lipid content as a function of
postnatal time are taken from Neville et al.
(1991) (see Supplemental Material online at
http://www.ehponline.org/members/2008/
10917/suppl.pdf). Placental diffusion constant
(PAF) describing the exchange between the
mother and the baby is given an arbitrary value
of 1, because the model outputs in the woman
(i.e., blood concentrations) are virtually not
inﬂuenced by this value. 
Tissue:blood and milk:blood partition coefﬁ-
cients are estimated using Poulin and Krishnan’s
(1996) approach based on tissue water and lipid
composition (Price K et al. 2003):
, [6]
where Kow represents n-octanol:water partition
coefﬁcient, and Fl and Fw stand for the lipid
and water fraction, respectively, for either tissue
(subscript t) or blood (subscript b). Tissue com-
position is taken from Price K et al. (2003) (see
Supplemental Material online at http://www.
ehponline.org/members/2008/10917/
suppl.pdf). Slowly perfused tissues compart-
ment composition is calculated as scaled lipid
and water content of muscles, skin, and heart
taken from the same paper as follows:
, [7]
where F is the fraction of either lipid or water
for the whole compartment, whereas Fi and Vi
are the fraction of either lipid or water and the
volume for organs included in the compart-
ment, respectively. Richly perfused tissues
compartment composition is calculated with
the same equation (Equation 7). The richly
perfused tissue compartment includes the
lungs, kidneys, reproductive organs, spleen,
glands, intestinal tract, and stomach tissues.
The organ volumes (Vi) used for the calcula-
tion of this compartment composition are
those at 18 years of age calculated with the
equations in Haddad et al. (2001). The parti-
tion coefﬁcients for richly and poorly perfused
tissues compartments are calculated with
Equation 6 using these scaled composition
parameters. Because of the lack of data, the
richly perfused tissues compartment partition
coefﬁcient is used for the mammary tissue, pla-
centa, and uterine tissue compartments.
Because no information is available on fetus
compartment composition, we assessed the
impact of different partition coefﬁcients on the
model outputs. The lack of signiﬁcant impact
of the tissue:blood partitioning for the fetus
compartment on the toxicokinetic profile of
the mother led us to arbitrarily give it the parti-
tion coefficient of the richly perfused tissues
compartment.
Metabolism is parameterized from half-
life values for the compounds to be studied.
This assumes that POP elimination is essen-
tially attributed to hepatic clearance. First, the
intrinsic clearance values per kilogram of liver
(CLintC) are calculated for the physiologic
parameters at the age of half-life [HL(h)]
measurements:
, [8]
where Ehage = CLage ⁄Qlage , [9]
CLage = (ln2 ⁄HL(h)) × Vdage , [10]
Vdage = (ΣPage × Vtage ) + Vbage , [11]
where Ql is the blood ﬂow to the liver, Vl is the
volume of the liver, CL is the clearance for the
studied compound, Vd is the volume of distrib-
ution, P is the tissue:blood partition coefﬁcient,
Vt is the volume of tissues, and Vb is the vol-
ume of blood. The subscript age means that the
parameters are calculated with the physiologic
features at the age of individuals sampled for
half-life value measurements, whereas the sub-
script (h) means that the values of half-lives
were in hours. Extraction ratios are calculated
from CLintC, which is assumed to be age invari-
ant, and from the liver volume and blood ﬂow,
which change as a function of age, as follows:
[12]
The liver weight–adjusted hepatic extrac-
tion ratio is used for the calculation of the
metabolism rate. Although recent modeling
studies (e.g., Clewell et al. 2004) introduced
gene ontology data in their model to reflect
age variations in intrinsic clearance, this was
not considered in the present simulations
because of the relative little impact it has
shown on lifetime kinetics and on the data
interpretation in this study (simulations not
shown). If needed in the future, such informa-
tion can easily be incorporated into the model. 
Model simulations. Different scenarios
were simulated to assess the impact of different
physiologic processes or changes that can occur
during the lifetime of a woman on the toxico-
kinetic proﬁle of POPs as well as on the blood
concentration at age of diagnosis. The input
parameters that were changed for the simula-
tions were breast-feeding in childhood, level of
exposure through food intake, body weight
and body height in function of age, number of
pregnancies, age at child birth(s), lactation
periods, and chemical properties for the chosen
pollutants (log Kow and hepatic extraction
ratio). All simulations used as input the normal
body weight profile and the height profile
depicted in Figure 2, unless stated otherwise. 
Three pollutants were chosen for the pre-
sent studies: PCB-180, PCB-153, and HCB,
chosen for their relevant concentrations found
in human blood and adipose tissue as well as
the fact that they differ in their Kow and half-
life. Log Kow was 6.72 for PCB-153, 7.21 for
PCB-180, and 5.73 for HCB [Agency for
Toxic Substances and Disease Registry
(ATSDR) 2000, 2002]. Hepatic extraction
ratios were calculated as described in the para-
meterization section from the approximate
half-lives of the chemicals, which were
27.5 years for PCB-153, 9.9 years for
Eh
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(ATSDR 2000; To-Figueras et al. 2000). 
Although the actual food consumption lev-
els of these POPs declined from the 1970 to the
1990s, it was kept constant for the purpose of
the modeling effort. However, the actual levels
may be entered as a variable into the model. For
all simulation scenarios, the level of exposure
through ingestion of contaminated food was set
as a background daily exposure of 10 ng/kg
body weight/day (unless speciﬁed otherwise). 
Impact of breast-feeding in childhood. In
this first set of simulations, the period of
breast-feeding was set to 6 months, with a con-
stant concentration of 2 µg/L to compare the
kinetics of the three chemicals. The volume of
milk ingested was modeled with the same
equation used for the breast-feeding periods of
the exposed woman. The milk concentrations
used in these simulations were arbitrarily cho-
sen and do not necessarily reﬂect speciﬁc actual
levels of contaminants, although similar POP
milk levels were found in the literature
(Dewailly et al. 1996; Solomon and Weiss
2002). The purpose is simply to show how
breast-feeding in childhood will impact the
LTP of a given individual.
Impact of body weight change. For some
simulations, the body weight parameter was
varied to investigate the inﬂuence of adipose
tissue volume and its variation throughout the
lifetime of a woman on the tissue pollutant
concentration. Body weight and body height
profiles used in this study are depicted in
Figure 2. The normal weight and overweight
scenarios represented linear increases in weight
from 50 kg at 14 years of age to 70 and 90 kg,
respectively, at 25 years of age. Weight loss
scenario followed the overweight proﬁle with a
drop from 90 to 70 kg on a 10-year interval
between 25 and 35 years of age. 
Impact of pregnancy and lactation. We
performed simulations for several pregnancy
history scenarios. The number of pregnancies
was either one or two. Lactation period length
effect on tissue or blood concentration was
also assessed; lactation periods chosen for
these simulations were 6 and 12 months. 
Differences in toxicokinetic proﬁles for a
given blood concentration at the age of diag-
nosis. For a given POP blood concentration,
toxicokinetics proﬁles were obtained for simu-
lations in women having different physiologic
histories (i.e., different number of pregnancies,
period of lactation, weight proﬁle, and expo-
sure). This was done to assess how much the
lifetime internal exposure can differ for a given
POP blood concentration at the age of diagno-
sis. The exposure values were optimized to
reach the same blood concentration at 55 years
of age for different physiologic histories. 
Results
Impact of breast-feeding in childhood. We used
the PBPK model to investigate the potential
impact of additional early exposure through
breast-feeding in childhood. For this purpose, a
scenario considering breast-milk drinking for a
period of 6 months was compared with a sce-
nario where the woman was not breast-fed
(Figure 3A). The milk concentration was set at
2 µg/L, and the background oral exposure was
set as a daily intake of 10 ng/kg body weight.
Scenarios were simulated for a woman with a
normal body weight proﬁle. For the breast-fed
female scenario, the blood concentration at the
end of the milk-drinking period reaches
1.87 µg/L for PCB-153, 1.81 µg/L for
PCB-180, and 1.74 µg/L for HCB. These con-
centrations are even higher then those at the age
of diagnosis (i.e., 55 years of age). At 5 years of
age, the difference between the two scenarios
was important for all three pollutants, because
the blood concentration was about 2-fold
higher for the breast-fed woman. However, by
20 years of age, these differences almost com-
pletely disappeared. It can also be observed that
blood concentrations at 55 years of age cannot
distinguish breast-fed from non-breast-fed indi-
viduals, even though internal concentrations in
the breast-fed group were very high in infancy. 
Impact of body weight change. We also
assessed the impact of body weight on POP
kinetics with the use of various proﬁles shown
in Figure 2. All these simulations used the
same body height profile (Figure 2). Using
these three physiologic profiles, simulations
considering a 6-month period of milk drink-
ing in childhood (milk concentration, 2 µg/L)
and a daily exposure to 10 ng/kg of the chemi-
cals were performed for the three chemicals
studied (Figure 3B). Simulations show that
both the normal and the overweight scenarios
display similar kinetic proﬁles, despite the fact
that PCB blood concentration at 55 years of
age is slightly higher in the overweight proﬁle
than for the normal weight proﬁle. A weight
loss between 25 and 35 years of age raises the
immediate blood POP concentrations consid-
erably. The effect is more pronounced and
lasts up to 55 years of age for PCB-153, where
the blood concentrations at 35 years of age are
1.13 µg/L and 1.38 µg/L for the normal
weight and weight loss proﬁles, respectively. 
Impact of pregnancy and lactation. We
also investigated the impact of pregnancy and
subsequent breast-feeding on blood POP con-
centrations. First, scenarios with pregnancy
alone and pregnancy followed by a 12-month
lactation starting at 30 years of age were simu-
lated to compare the respective effect of these
two factors (Figure 3C). For PCB-153, the
blood concentration at 31 years of age is much
lower in the woman who lactated for
12 months (0.53 µg/L blood) than in the
woman without lactation (1.01 µg/L blood).
The difference is still present at 55 years of
age, although smaller than at 31 years of age.
For PCB-180, lactation has a small effect on
the blood concentration at 55 years of age,
whereas for HCB it has no impact. Simula-
tions show that the pregnancy alone induces a
small drop in the blood concentration that
rapidly returned to prepregnancy levels after
postpartum physiologic changes (Figure 3C,
normal lines). 
We assesssed the impact of the length of
the lactation period. Simulations for two lacta-
tion period lengths show that longer lactations
have a greater impact on the blood concentra-
tion (Figure 3D). For PCB-153, the blood
concentration at 55 years of age is 1.39 µg/L
PBPK modeling for lifetime POP exposure assessment
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Figure 2. Body weight and body height profiles used for the simulations: (A) body height, (B) normal
weight, (C) overweight, and (D) weight loss proﬁles. The normal weight and overweight scenarios repre-
sent linear increases in weight from 50 kg at 14 years of age to 70 and 90 kg, respectively, at 25 years of
age. Weight loss scenario followed the overweight profile with a drop from 90 to 70 kg on a 10-year
interval between the ages of 25 and 35 years.
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C Dfor a 6-month lactation and 1.25 µg/L for a
12-month lactation starting at 35 years of age.
The difference between the two lactation
periods is small for PCB-180 and negligible
for HCB when only blood concentration at
55 years of age is considered. 
POP toxicokinetic proﬁles were also com-
pared for lactations of the same duration but
held at different ages. Two scenarios were
compared: child birth at either 20 or 35 years
of age, followed by a 12-month breast-feeding
period (Figure 3E). As expected, POP kinetics
differ between the two scenarios. The effect of
a lactation period later in life influences sig-
niﬁcantly the blood concentration at 55 years
of age for PCB-153, whereas this effect is
minimal for PCB-180 and practically absent
for HCB in the simulated scenarios. 
Differences in toxicokinetic profiles for a
given blood concentration at diagnosis. To
demonstrate that the same blood concentration
at 55 years of age can be the result of com-
pletely different kinetic proﬁles, we compared
two scenarios with different lifetime profiles
(Figure 3F). The first scenario represents a
woman who was not breast-fed in childhood,
was never pregnant, and was exposed through-
out life to the background level of 10 ng/kg/day
for each of the three pollutants. The second sce-
nario is that of a woman who was breast-fed for
6 months with breast milk at a POP concentra-
tion of 2 µg/L, had two pregnancies, one at 35
and one at 40 years of age, followed by a
12-month lactation period each time. To obtain
a ﬁnal concentration at 55 years of age identical
to the one in the ﬁrst scenario, the daily expo-
sure levels were optimized to the following
levels: 18.7 ng/kg/day for PCB-153, 13.8
ng/kg/day for PCB-180, and 11.6 ng/kg/day for
HCB. These simulations yielded completely dif-
ferent kinetic proﬁles despite resulting in the
identical blood concentration at 55 years of age
(Figure 3F). The blood concentration at
34 years of age showed the greatest difference,
especially for PCB-153, where approximately a
2-fold higher level was calculated for the breast-
feeding/pregnancy/higher exposure scenario
(2.03 µg/L blood) than for the no breast-
feeding/no pregnancy/background exposure sce-
nario (1.07 µg/L blood). 
Discussion
Over the last decades, many environmental epi-
demiology studies have focused on the possible
link between exposure to POPs and the devel-
opment of breast cancer, but no clear overall
conclusion could be drawn from the different
findings. Discrepancies among conclusions
from the various studies might be related to the
false assumption that a unique late-life sam-
pling reﬂects lifetime POP exposure. Our study
supports this contention and proposes a new
tool that could reduce this uncertainty in expo-
sure assessment by simulating lifetime toxico-
kinetics of POPs in women. 
The PBPK model built in this study can
overcome exposure assessment problems by
simulating normal development (i.e., growth,
blood flows) and various historical events
within the lifetime of a woman [i.e., breast
feeding, changes in body mass index (BMI),
pregnancy] to obtain the lifetime toxicokinetics
of POPs. Using this model, we simulated sev-
eral exposure and physiologic scenarios to assess
the impact of different parameters on POP
blood concentrations from 0 to 55 years of age. 
Although in utero exposure is known to
occur through placental diffusion, body burden
at birth was set to 0. This methodologic choice
relies on two facts: a) fetus tissue concentration
estimation would require information on the
exposure of the mother to simulate the placental
Verner et al.
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Figure 3. Toxicokinetic profiles for PCB-153, PCB-180, and HCB blood concentration for (A) normal body
weight history and 10 ng/kg/day exposure to each of these chemicals for a woman who was not breast-
fed in childhood (blue line) or breast-fed for 6 months (black line); (B) normal weight (gray line), weight
loss (black line), or overweight (blue line) proﬁles and 10 ng/kg/day exposure to each of these chemicals
for women who were breast-fed for 6 months in childhood; (C) normal body weight history and 10
ng/kg/day exposure to each of these chemicals for a woman who was breast-fed for 6 months in child-
hood and had a pregnancy at 30 years of age followed by no lactation (blue line) or a 12-month lactation
period (black line); (D) normal body weight history and 10 ng/kg/day exposure to each of these chemicals
for a woman who was breast-fed for 6 months in childhood and had a pregnancy followed by a 12-month
lactation period at 20 years of age (blue line) or 35 years of age (black line); (E) normal body weight history
and 10 ng/kg/day exposure to each of these chemicals for a woman who had a pregnancy at 35 years of
age followed by a 6-month lactation period (blue line) or a 12-month lactation period (black line); (F) normal
body weight history for a woman who was exposed to 10 ng/kg/day of each of the three chemicals and
had no pregnancy (black line) or was breast-fed for 6 months in childhood, was exposed to 18.7 ng/kg/day
PCB-153, 13.8 ng/kg/day PCB-180, 11.6 ng/kg/day HCB, and who had two pregnancies at 35 and 40 years of
age followed by 12-month lactation periods (blue line). 
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HCBtransfer, and b) the baby’s body burden at
birth is rapidly diluted by increasing tissue vol-
umes and therefore has a small impact on life-
time toxicokinetics when compared with breast
milk consumption (Clewell et al. 2004;
Kreuzer et al. 1997). 
Simulations showed that although preg-
nancy alone did not have a strong impact on
blood POP concentrations, lactation exerted
major changes in the toxicokinetic proﬁles. The
longer and later in life a lactation period occurs,
the greater its impact on blood POP concentra-
tion of the woman at 55 years of age. Thus,
quantitative information on lactation is critical
when evaluating past exposure to POPs.
Moreover, simulations showed that body
weight variations throughout life seemed to
have a greater impact on blood POP concentra-
tions than body weight level itself. A loss of
weight can be regarded as a decrease in the adi-
pose tissue volume in which POPs are preferen-
tially stored, a phenomenon that leads to the
unloading of POPs into blood. It has been pre-
viously shown that PCB-153, HCB, β-hexa-
chlorocyclohexane, p,p´-DDE, and Aroclor
1260 levels in blood increase with weight loss
(Imbeault et al. 2002). Therefore, BMI changes
should be regarded as an important factor in
POP kinetics. New approaches in exposure
assessment that consider physiologic parameters
such as BMI and lactation were developed by
Wolff et al. (2005) with the use of ﬁrst-order
pharmacokinetic and predictor-based multivari-
ate models. They concluded that possible expo-
sure misclassiﬁcations in epidemiologic studies
can occur if the impacts of BMI and lactation
on POP concentrations are ignored. In accor-
dance with such results, the current study
clearly showed that sampling at the age of diag-
nosis is a questionable end point for lifetime
exposure estimation. A more recent study from
Wolff et al. (2007) stresses the importance of
considering pharmacokinetic variability in epi-
demiologic studies. PBPK modeling as pro-
posed here is particularly well suited for such
considerations The use of PBPK models such as
the one reported in our manuscript go much
further than Wolff’s strategy in considering
pharmacokinetics. This new approach is being
proposed to epidemiologists. Instead of simply
proposing pharmacokinetic factors such as BMI
as other covariables in the epidemiologic stud-
ies, we suggest directly using PBPK model esti-
mates of blood or tissue concentrations during
different periods of life for each subject of the
study to analyze if there is a relationship
between disease and internal exposure.
We investigated the impact of breast milk
consumption in childhood on internal exposure
by comparing POP venous concentration in
breast-fed and a bottle-fed women. Results
showed that early-life blood POP concentra-
tions are strongly influenced by breast-milk
drinking for the ﬁrst years of life, but that these
effects are almost fully attenuated by 20 years of
age. These ﬁndings are supported by a study on
a Faroese birth cohort in which the primary
contributors to the serum total PCB concentra-
tions at 7 and 14 years of age were breast-feed-
ing and blubber consumption, respectively
(Barr et al. 2006). The work reported herein
showed that blood or tissue POP concentration
at the age of diagnosis does not reflect the
important body burden resulting from early life
breast-feeding, a possibly important time
window of exposure.
By simulating the lifetime blood concen-
trations for two distinct exposure and life his-
tory scenarios with the same level at 55 years of
age, this study showed the poor predictive
value of late-life sampling for past exposure
assessment. Late lactations can dramatically
decrease POP concentrations and lead to lower
blood concentrations at the age of diagnosis,
even for a high-exposure proﬁle. To eliminate
this artifact, it is crucial that the estimation
takes into account such physiologic events.
This PBPK model enables the considera-
tion of chemical-speciﬁc parameters affecting
distribution (log Kow) and elimination (half-
life). The simulations performed with the three
contaminants showed that blood PCB-153 lev-
els were more sensitive to the main factors—
that is, lactation and body weight change—
than those for PCB-180 or HCB. This can be
explained by their different half-lives, a parame-
ter that strongly correlates with the time
required for the pollutant to reach steady state
in the body. Chemicals with a shorter half-life
reach steady state more rapidly, leading to the
faster attenuation of the impact that these phys-
iologic events may have on blood concentra-
tion. On the other hand, the log Kow is unlikely
to account for differences in POP toxicokinet-
ics, because it has been reported that com-
pounds with a log Kow value > 4 will partition
similarly between blood and organs (Haddad
et al. 2000). Like physiologic parameters,
interindividual variability also exists in half-life
values as well as blood and adipose tissue lipid
content, which are sensitive parameters of the
PBPK model (see Supplemental Material
online at http://www.ehponline.org/members/
2008/10917/suppl.pdf). Apart from doing a
toxicokinetic study in each individual, there
currently exists no method to estimate half-lives
in individuals. Similarly, determining lipid frac-
tions in blood and adipose tissue of individuals
represents another difﬁculty, and such a prac-
tice can be very costly. Using average values of
these parameters is an acceptable surrogate,
because they lead to prediction errors under a
1.5-fold difference in blood concentrations in
the case of intrinsic clearance and 1.8-fold in
the case of lipid composition in adipose tissues
and blood (see Supplemental Material online at
http://www.ehponline.org/members/2008/
10917/suppl.pdf). 
The PBPK model developed herein reﬁnes
the assessment of past tissue exposure by incor-
porating physiologic processes that greatly
affect POP kinetics. The use of such a tool
should permit epidemiologists to better assess
past exposure and to investigate the potential
critical windows of exposure to POPs in cancer
development, a commonly reported concern in
epidemiology studies. The importance of expo-
sure assessment for different critical time win-
dows is supported by studies on breast cancer
incidence among Japanese women who were
exposed to radiation; these studies show that
exposure at a lower age has a higher impact on
cancer development than exposure at later-life
stages (Hoel and Dinse 1990; Tokunaga et al.
1994). Moreover, a recent study reported that
exposure to p,p´-DDT early in life may
increase the risk of breast cancer (Cohn et al.
2007). By using estimated LTPs and internal
exposure levels for different time frames, this
hypothesis could be further addressed. 
Furthermore, the toxicity of certain POPs
may not be attributable entirely to parent
compound. Some evidence indicates that
metabolites may also elicit a biochemical or
toxic response (Machala et al. 2004; Meerts
et al. 2004; Safe 1994; You et al. 2006).
Because the PBPK model describes the metab-
olism of the chemicals, the amount of metabo-
lites formed in different periods of life can be
assessed and used for epidemiologic analysis in
the same way that we use internal concentra-
tions of the parent compound. Thus, PBPK
modeling can also add another dimension to
POP epidemiologic studies.
To perform simulations, information on
the proposed important variables to be used as
inputs in the model must be gathered within
the epidemiologic questionnaire. The model
was constructed so that it requires information
on body weight and height as a function of age.
Information on pregnancy and lactation peri-
ods is also a prerequisite to model simulation.
This information must be associated with the
age of the woman at birth of her children and
the duration of the lactation periods. The
model can easily include any information on
exposure levels that could vary as a function of
changes in dietary lifestyle (e.g., increase in ﬁsh
consumption or in fatty foods for certain peri-
ods of life) as well as geographic/temporal mon-
itoring data on environmental levels of selected
pollutants. Once these parameters are included
in the model, the exposure scenario can be opti-
mized with the use of information on both esti-
mated exposure and blood or tissue samples. 
Although the proposed PBPK model frame-
work for POP lifetime exposure assessment in
women is constructed on validated descriptions
of absorption, distribution, metabolism, and
excretion of various POPs in rodents or
humans, further studies are needed to validate
the model. The model proposed herein can be
PBPK modeling for lifetime POP exposure assessment
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ments/modiﬁcations can be made to incorpo-
rate additional toxicokinetic processes that may
be speciﬁc to particular POPs (e.g., diffusion
limitation, plasma or tissue protein binding) if
relevant for a lifetime scale in humans.
Conclusion
This study is the ﬁrst to propose a PBPK model-
ing approach for the assessment of lifetime inter-
nal exposure to POPs in the context of
epidemiologic studies. The proposed model has
the potential to be used in environmental epi-
demiology research to reduce the uncertainty in
past tissue exposure estimation. This approach
can not only strengthen the validity and repro-
ducibility of studies on the impact of POPs on
breast cancer incidence in humans, but also help
to assess the effect of exposure during critical
time windows in breast cancer development and
other late-life diagnosis pathologic end points.
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